Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.

Saved in:
Bibliographic Details
Title: Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
Authors: Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Rodriguez LP, Breder V, Ostoros G, Hanes V
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 May 15; Vol. 25 (10), pp. 3193.
Publication Type: Journal Article; Published Erratum
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-19-1098